Filgrastim is a trusted and widely used colony-stimulating factor (CSF) therapy that promotes the production of neutrophils, a type of white blood cell vital for combating infections. This product is essential for patients undergoing chemotherapy or bone marrow transplantation, as it helps to mitigate the risk of severe neutropenia. Filgrastim accelerates the recovery of white blood cell counts, enhancing the body's ability to fight infections and improving patient outcomes. Developed by Amoytop Biotech, Filgrastim is manufactured to the highest standards of quality and efficacy, ensuring reliable and effective treatment. Our focus on innovation and patient care drives the continuous improvement of Filgrastim, making it an indispensable part of supportive care in oncology and hematology.
Specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..
